Targeted Therapy Combinations: VVIP, VIPOR, and VIPOR-P Clinical Trials
This event will not be live-streamed; it will be recorded on March 29th. You can submit your questions in advance by clicking "notify when available" above and enter your question in the box. We will ask the submitted questions during the Q&A at the end.
In this podcast episode, Dr. Christopher Melani will share about three important trials he has been working on at The National Institute of Health in Bethesda, Maryland. The VVIP, VIPOR, and VIPOR-P studies are targeted therapy combinations that could be the future of lymphoma treatment. We will be discussing the trial designs, patient eligibility, and how these new treatments could improve lymphoma patient outcomes.
Thank you to our episode sponsor, Regeneron.
Dr. Christopher Melani
Dr. Melani is a Staff Clinician and a clinical researcher specializing in lymphoma. His areas of interest include the use of novel therapies and drug combinations for the treatment of lymphomas as well as novel methods of molecular monitoring of disease and response to treatment, such as circulating tumor DNA (ctDNA).
Kat Richardson
Kat is from Lehi, Utah and is the Health Education Manager for lymphoma. She has worked in healthcare for a decade now, and earned her degree in Community Health Education and Promotion. Kat is passionate about disease prevention as well as improving quality of life and health equity. She enjoys reading, hiking, baking, ice skating, gardening, time with her family and friends, and most of all, spoiling her nieces and nephew.